Pivotal Phase 3 VERITAC-2 clinical trial results presented at ASCO demonstrate 2.9-month improvement in median progression-free survival when compared to fulvestrant in second line-plus patients with ...

Researchers from Mass General Brigham will present research discoveries and outcomes from clinical trials in cancer at the ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced that ten abstracts have been accepted for presentation at ...

Infusion centers nationwide are struggling with increasing patient volumes, staff burnout, and limited chair capacity. Chicago-based Northwestern Medicine tackled these challenges head-on at its ...

Results showed a significant association between orthopedic sports medicine fellowship programs that publicly commit to diversity, equity and inclusion statements with a higher representation of women ...

The problem of using male anatomy as the default in medicine is that it doesn’t always read across to female bodies.

Poster presentations across all programs, including data from HELIOS long-term extension trial of bitopertin in erythropoietic protoporphyria (EPP), additional durability data from Phase 1b study of ...

“The data presentation at ARVO is part of ANI’s ... Ophthalmology at Boston University Chobanian & Avedisian School of Medicine. Cortrophin Gel is a prescription medicine that is injected ...

today announced the simultaneous publication of landmark clinical data on its lead investigational drug D3S-001 in Nature Medicine and oral presentation of updated results at the 2025 American ...

Yonsei University College of Medicine. "We believe it is a truly new-generation KRAS G12C inhibitor with the potential to overcome the limitations of the first-generation inhibitors and become a ...

D3 Bio Announces Nature Medicine Publication and AACR 2025 Presentation Highlighting D3S-001 as a Next-Generation KRAS G12C Inhibitor with Best-in-Class Potential D3 Bio, a clinical-stage ...

today announced the simultaneous publication of landmark clinical data on its lead investigational drug D3S-001 in Nature Medicine and oral presentation of updated results at the 2025 American ...